摘要
核输出蛋白1(XPO1)是人体关键的核输出蛋白,也是血液肿瘤治疗的有效靶点。塞利尼索作为首个XPO1抑制剂,已被美国食品药品管理局(FDA)批准用于复发难治多发性骨髓瘤(MM)、弥漫大B细胞淋巴瘤(DLBCL)的治疗。国内外多项临床研究结果显示,塞利尼索单药或联合用药疗效好且安全性可控。在我国,塞利尼索于2021年12月14日获批复发难治MM的适应证,为临床医师带来新的治疗选择。专家组成员经过充分讨论,并汇总国内外权威指南和文献,制定了塞利尼索在血液系统疾病中的临床应用指导原则,旨在为我国临床医师用药提供参考。
Exportin-1(XPO1)is the key nuclear transport protein of human body and an effective target to treat hematological tumors.As the first XPO1 inhibitor,selinexor was approved by Food and Drug Administration(FDA)of the United States for relapsed/refractory multiple myeloma(MM)and diffuse large B-cell lymphoma(DLBCL).Many domestic and foreign clinical trials have shown that selinexor has encouraging efficacy and manageable safety profile either when used alone or in combination.In China,selinexor was approved for the treatment of relapsed/refractory MM in 14 December in 2021,which brings new treatment options to clinicians.Based on the latest domestic and foreign authoritative guidelines and literature,the expert group discussed and developed the guiding principles of selinexor in hematological system diseases to provide a reference for Chinese clinicians.
出处
《白血病．淋巴瘤》
CAS
2023年第2期65-73,共9页
Journal of Leukemia & Lymphoma
作者简介
通信作者:马军,哈尔滨血液病肿瘤研究所,哈尔滨150010,Email:majun0322@126.com
